Main Menu
MSAA
  • Toll-Free Helpline Call Us Toll Free (800) 532-7667 Search
  • Get MS Updates
  • Información en Español
  • Donate
  • Skip main navigation
MSAA logo
  • MS Information
    • MS Overview & Glossary
    • Newly Diagnosed
    • Symptoms
    • Treatments
    • COVID-19 and MS
    • Patient Support Programs
    • Clinical Trials Search
    • Publications
    • Latest News from MSAA
    • Videos and Webinars
    • Podcasts from MSAA
    • Toll-free Helpline & Chat
    • Información en Español
    • MS FAQs and Glossary
  • How MSAA Can Help
    • Toll-free Helpline & Chat
    • Publications
    • Videos and Webinars
    • Cooling Products
    • Equipment Products
    • MRI Access Program
    • Educational Programs
    • Shared Decision-Making Tools
    • Overall Wellness
    • Online Aquatic Center
    • FAQs
  • Living with MS
    • My MSAA Community
    • MS Conversations Blog
    • Multiple Sclerosis Implementation Network™ (MSIN™)
    • My MS Journey
    • My MS Manager™ Mobile App
    • MS Relapse Resource Center
    • Overall Wellness
    • Online Aquatic Center
    • Educational Programs
  • Donate
    • Make A Donation
    • Honor and Memorial Donations
    • Become a Monthly Improver
    • Planned Giving
    • Other Ways to Give
      • Donor-Advised Funds
      • Vehicle Donation
      • Matching Gifts
      • Shop & Support MSAA
    • Donation FAQs
  • Get Involved
    • Special Events
    • Art Showcase
    • Do-It-Yourself Fundraiser
    • Multiple Sclerosis Implementation Network™ (MSIN™)
    • Partnerships
    • Volunteer With MSAA
    • FAQ
  • Calendar
  • About MSAA
    • Mission and Overview
    • MS Awareness Month
    • MSAA Achievements
    • Contact Us
    • Board of Directors
    • Healthcare Advisory Council
    • African American Advisory Board
    • Hispanic/Latinx Advisory Board
    • MSAA Strategic Plan
    • Navigating MS
    • MS Coalition
    • Annual Report
    • Financial Information
  • Search
  • Home
  • Kesimpta®
Back to Treatment Guide

Kesimpta®

ofatumumab

Quick Facts

Kesimpta® is a monoclonal antibody and anti-inflammatory disease-modifying therapy that depletes white blood cells called B cells.

Self-injected under the skin

Monthly

Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS

Potential Benefit:

Tested against active comparator, Kesimpta showed:

  • Reduced relapse by 51%-59%
  • Reduced likelihood of disability progression by 34%
  • 94%-98% fewer Gd + T1 lesions on MRI

Common Potential Side Effects

Headache and upper respiratory tract infection (URTI), including sore throat, runny nose. Injection-related reactions (fever, headache, muscle pain, chills, and fatigue). Local injection site reactions (redness, pain, itching, and swelling).

Prescription Assistance:

Alongside Kesimpta >

For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.

Hear from the Expert
Erica M. Rivas-Rodriguez, MD
Neurologist and MS Specialist, Baylor Scott & White Health
Erica M. Rivas-Rodriguez, MD
“Trying to figure out and understand what these different medications are going to do, how they’re going to help you, it can be overwhelming.”

DRUGMAKER

Novartis

HOW Kesimpta® WORKS

Kesimpta®, a monoclonal antibody, binds to a protein on the surface of immune cells, white blood cells called B lymphocytes or B cells. This depletes B cells, preventing them from stripping the myelin sheath and causing nerve damage.

FDA-Approved

Kesimpta® was FDA-approved in 2020 to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Potential Side Effects

Upper respiratory tract infection (URTI), including sore throat, runny nose, and headache, as well as headache unrelated to a URTI. Serious but less-common adverse events include infections, hepatitis B virus (HBV) reactivation, and a weakened immune system. A possible serious side effect is progressive multifocal leukoencephalopathy (PML), a rare brain infection that usually leads to death or severe disability over a period of weeks or months.

OTHER KEY INFORMATION

Testing completed prior to starting Kesimpta® includes:

  • Perform hepatitis B virus (HBV) screening
  • Test for quantitative serum immunoglobulins
  • Consider: Complete Blood Count with differential, Comprehensive Metabolic Panel, T and B cell subset, QuantiFERON-TB Gold test, urinalysis and cultures

Testing completed after starting Kesimpta® includes:

  • Complete Blood Count with differential, Comprehensive Metabolic Panel, T and B cell subset, immunoglobulins (IgG and IgM) every six months, consider urinalysis with culture and sensitivity

Patient advocates talk about
their treatment experience

  • Kristie Salerno Kent
    MS Advocate, Patient Advocacy Consultant
    Kristie Salerno Kent
    “I have had situations where treatments aren’t approved at first. My doctors, nurses, they actually go to bat for me and made it happen.”
  • Azure Antoinette
    MS Advocate
    Azure Antoinette
    "I will be undergoing my first disease-modifying therapy to help treat multiple sclerosis in my body and while I’m very nervous, I am equally as excited and looking forward to the positive effects of how I will feel physically, and mentally, and emotionally."
  • Damian Washington
    MS Advocate
    Damian Washington
    “Nobody’s going to be looking out for your best interests better than you.”
  • Cathy Chester
    MS Advocate
    Cathy Chester
    “I think it’s really important to talk about how to age with this illness.”
  • Lauren Hutton-Work
    MS Advocate
    Lauren Hutton-Work
    “Just because you have this disease does not mean that your work life should be awkward or uncomfortable.”
  • Chernise Joseph
    MS Advocate
    Chernise Joseph
    “My first neurologist was a frontline neurologist, he wasn’t an MS specialist.”
  • Julian Gamboa
    MS Advocate
    Julian Gamboa
    “If you’re newly diagnosed with multiple sclerosis remember it’s always okay to get a second opinion.”
  • Lauren and Sam Alcorn
    MS Advocates
    Lauren and Sam Alcorn
    “Our future is uncertain and we have to enjoy each other and love each other in the present.”
  • Shawn Feliciano
    MS Advocate
    Shawn Feliciano
    “I want to know what medications might work best for someone who’s Hispanic.”
  • Darlene Feigen
    MS Advocate
    Darlene Feigen
    “The sooner you get on a therapy the better it is in the long run.”
  • Birgit Bauer
    MS Advocate
    Birgit Bauer
    “At the end of the appointment you should have an answer to the most important questions.”
  • Ellen Tutton
    MS Advocate
    Ellen Tutton
    “I looked up all the different disease-modifying therapies and compared them to my lifestyle.”
  • Victoria Marie Reese
    MS Advocate
    Victoria Marie Reese
    “I’m trying to show my daughter that taking care of yourself is cool.”
    • MSAA logo
    • (800) 532-7667
    • msaa@mymsaa.org
    • MSAA is a 501(C)(3) nonprofit registered in the US under EIN: 22-1912812.Copyright ©2025 Multiple Sclerosis Association of America.Reproduction of material from any mymsaa.org pages without written permission is strictly prohibited.
    • GET EMAIL UPDATES
    • Privacy Policy and Terms of Use
    • Donor Privacy Policy
    • Financial Information
    • Información en Español
    • Contact Us
    • GET SMS UPDATES:
      Text
      MSAA to 75101

       
      Why sign up?
      You’ll get important MS-related news, crucial updates about our programs, and easy ways to support the MS community right from your phone.
       
      By participating, you agree to the terms and privacy policy for recurring autodialed campaign & donation messages from MSAA to the phone number you provide. No consent required to buy. Message and data rates may apply.
    • Guidestar Logo
    • Charity Navigator
    • America's Charities
    • Facebook
    • Twitter
    • Instagram
    • Tik Tok
    • Pinterest
    • YouTube
    • LinkedIn
    • ESSENTIAL
    • Accessibility Statement

Aug 18, 2022 @ 6:25 am

×